Long-Term Safety and Efficacy of Fremanezumab for the Prevention of Cluster Headache
- Study Title
- A Study to Explore the Long-Term Safety and Efficacy of Fremanezumab (TEV-48125) for the Prevention of Cluster Headache
- Teva Identifier
- TV48125-CNS-30058 | 2016-003172-43
- ClinicalTrials.gov Identifier
- NCT03107052
- Study Status
- Terminated
- Trial Condition(s)
- Cluster Headache
- Interventions
- Drug: Fremanezumab
- Study Description
- Please refer to ClinicalTrials.gov for a description of the trial
Key Participation Requirements
- Gender
- Female, Male
- Age group
- Adult, Older Adult
- Age Range
- 18 Years to 70 Years
- Trial Duration
- April 27, 2017 - June 11, 2019
- Phase
- Phase 3
